Clinical Trials Directory

Trials / Completed

CompletedNCT03176303

Study Using the SpinalStim Device Following Lumbar Fusion Surgery

A Multi-Center, Open-Label, Prospective Study of SpinalStim™ (MOP-SS) as Adjunctive Care Following Lumbar Fusion Surgery

Status
Completed
Phase
Study type
Observational
Enrollment
206 (actual)
Sponsor
Orthofix Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study examines the effect of adjunctive use of the SpinalStim bone growth stimulator on lumbar fusion rate in high risk subjects who have had lumbar fusion surgery. All participants will wear the bone growth stimulator for a minimum of 2 hours/day for 6 months.

Detailed description

The purpose of this post market prospective study is to examine the effect of the adjunctive use of the Orthofix SpinalStim™ device on lumbar fusion rate in high risk subjects who have undergone lumbar fusion surgery. High risk subjects are those who are currently using nicotine, who are having a multi-level fusion, who have had a prior failed fusion at any lumbar level, who are diabetic or who are osteoporotic. Because this is a post market prospective study, subjects who are enrolled in this study will be identified by the Investigator as needing lumbar fusion surgery and asked if they would like to participate in a study looking at the efficacy of lumbar fusion with adjunctive use of the SpinalStim bone growth simulator. The type of lumbar fusion surgery performed (lateral lumbar interbody fusion \[XLIF\], posterior lumbar interbody fusion \[PLIF\], anterior lumbar interbody fusion \[ALIF\], posterolateral fusion) is up to the Investigator; the subjects in the study must be agreeable to using the bone growth stimulator daily for 6 months post surgery.

Conditions

Interventions

TypeNameDescription
DEVICESpinalStimPEMF osteogenesis stimulator

Timeline

Start date
2017-06-28
Primary completion
2021-07-12
Completion
2021-07-12
First posted
2017-06-05
Last updated
2022-09-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03176303. Inclusion in this directory is not an endorsement.